CCM
AERI

CAAS Capital Management’s Aerie Pharmaceuticals AERI Stock Holding History

CAAS Capital Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-274,448
Closed -$4.05M – 647
2020
Q2 		$4.05M Buy
+274,448
New +$4.06M 0.13% 149

Other funds holding AERI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

CAAS Capital Management's AERI Position: Q3 2020 in Review

CAAS Capital Management sold out of Aerie Pharmaceuticals (AERI) in Q3 2020, closing a stake of 274,448 shares — an estimated $4.05M sold.

CAAS Capital Management first reported a position in AERI in Q2 2020 and held it in 1 quarter. The position peaked at $4.05M in Q2 2020. 148 funds tracked by Wall St. Rank hold AERI as of Q3 2020.

  • CAAS Capital Management reported no remaining Aerie Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • CAAS Capital Management sold 274,448 Aerie Pharmaceuticals shares in Q3 2020, an estimated $4.05M.
  • CAAS Capital Management first reported a position in Aerie Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • CAAS Capital Management's Aerie Pharmaceuticals position peaked at $4.05M in Q2 2020.
  • 148 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2020.

Based on CAAS Capital Management's 13F filing for Q3 2020, filed 9 Nov 2020.